<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00455728</url>
  </required_header>
  <id_info>
    <org_study_id>2-79-58035-005</org_study_id>
    <secondary_id>EUPAS7948</secondary_id>
    <nct_id>NCT00455728</nct_id>
  </id_info>
  <brief_title>A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth Disorders</brief_title>
  <acronym>iNCGS</acronym>
  <official_title>International Cooperative Growth Study (iNCGS) Post Marketing Surveillance Program for NutropinAq® [Somatropin (rDNA Origin) Injection]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, open label, observational, post marketing surveillance study of
      NutropinAq® in Austria, France, Germany, Italy, Spain, Romania and United Kingdom to collect
      long-term safety and effectiveness information on NutropinAq® during treatment of paediatric
      growth disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to collect long term safety and effectiveness information on
      Ipsen's growth hormone (GH) NutropinAq® regarding treatment of paediatric growth disorders
      for which GH is indicated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2006</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Every 3 months until study completion</time_frame>
    <description>Description and incidence of any Serious Adverse Event (SAE) and all related (serious and non-serious) Adverse Events (AEs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment height measurements until epiphyseal closure is achieved.</measure>
    <time_frame>Every 3 months until study completion</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">3690</enrollment>
  <condition>Growth Hormone Disorders</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Children treated with NutropinAq in the specialised paediatric endocrinology centres
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children of either sex who are treated with NutropinAq® for the treatment of growth
             failure

          -  Patients who are willing to comply with follow-up appointments throughout study
             participation

          -  Written informed consent signed by both parents or by the liable parent or by the
             legal guardian when applicable, and by the child when applicable

        Exclusion Criteria:

          -  Patients not treated with NutropinAq®

          -  Patients with closed epiphyses

          -  Patients with active neoplasia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline Sert, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ipsen Central Contact</name>
      <address>
        <city>Slough</city>
        <state>Berkshire</state>
        <zip>SL1 3XE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2007</study_first_submitted>
  <study_first_submitted_qc>April 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2007</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

